Vertex Cystic Fibrosis Treatment Gets CHMP Backing in Patients Ages 6-11

By Colin Kellaher

Vertex Pharmaceuticals Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of Kaftrio in a combination regimen with ivacaftor in children ages 6 to 11 with cystic fibrosis.

The Boston drug maker said the CHMP's recommendation covers patients who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

The European Commission, which generally follows the CHMP's recommendations, last year approved Kaftrio in combination with ivacaftor for the treatment of cystic fibrosis in patients ages 12 and older who have at least one copy of the F508del mutation.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

11-12-21 0810ET